EP601

About Epics Therapeutics

EPICS Therapeutics is a Belgian biotech founded in 2018, focused on the novel field of RNA epigenetics. Its core asset is EP102, a first-in-class, potent, and selective small-molecule inhibitor of METTL3, which is now in early clinical development for multiple solid tumors including NSCLC, pancreatic, ovarian, and colorectal cancers. The company is positioning itself at the forefront of translating epitranscriptomic research into clinical therapies, with a pipeline that also includes preclinical programs in immuno-oncology and autoimmune diseases. EPICS represents a high-risk, high-reward venture targeting a new therapeutic axis complementary to existing DNA- and protein-focused treatments.

Therapeutic Areas